https://wuxiapptec.com

Home | WuXi AppTecWuXi AppTec provides R&D & manufacturing services enabling companies in the pharmaceutical & biotech industries worldwide to advance discoveries.Home | WuXi AppTec Contact UsEN简繁About UsServicesPlatformNewsCareersInvestorsWuXi AppTecGlobal PlatformOne Vision Our VisionEvery Drug Can Be Madeand Every Disease Can Be TreatedBy Building an Open-access Platform with the Most Comprehensive Capabilities and Technologies in the Global Healthcare IndustryOur ValuesIntegrity & Dedication, Working Together & Sharing Success;Doing the Right Thing, Doing It Right. OverviewEnvironmental, Social and Governance (ESG)View ESG VideoAbout UsEnabling InnovationAs a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."SEE MOREServices and SolutionsAn Open Enabling PlatformEnabling more than 6,000 innovative customers from more than 30 CountriesSmall Molecule Drug R&D and ManufacturingCell Therapyand Gene TherapyDrug R&D and MedicalDevice TestingClinicalServicesSmall Molecule Drug R&D and ManufacturingCompany PlatformEnabling Anyone, Any CompanyTo Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare IndustryWuXi ChemistryProvides CRDMO servicesfor new drug development from discovery to commercialSEE MOREWuXi BiologyA full spectrum of biology services and solutionssupporting stand-alone and integrated projectsSEE MOREWuXi TestingSeamless drug and medical device testing servicesfrom preclinical testing to clinical trialsSEE MOREWuXi Advanced TherapiesGlobal CTDMOoffering an integrated end-to-end solution to accelerate time to market for cell and gene therapiesSEE MORENewsThe Latest News about WuXi AppTec WuXi AppTec Maintains AA MSCI ESG Rating for the Fourth Consecutive YearDespite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQWuXi AppTec Named to the FTSE4Good Index Series for the Second Consecutive YearWuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global CustomersWuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable OperationsWuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First TimeWuXi AppTec Maintains AA MSCI ESG Rating for the Fourth Consecutive YearShanghai, September 1, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently announced that it has maintained its AA MSCI (Morgan Stanley Capital International) ESG rating for the fourth consecutive year. The rating reflects WuXi AppTec’s commitment to incorporating environmental and social responsibilities into the company’s business strategies and operations.Read moreDespite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ- Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year - Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year - Net Profit Attributable to the Owners of the Company Reached RMB4,240 Million, and Diluted Earnings per Share (EPS) of RMB1.45 for the First Half - Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Reached RMB4,372 Million, and Adjusted Non-IFRS Diluted EPS of RMB1.50 for the First Half - Excluding COVID-19 commercial projects, Operating Cash Flow Up 48.3%/RMB1.50 billion Year-over-Year for the First Half Read moreWuXi AppTec Named to the FTSE4Good Index Series for the Second Consecutive YearShanghai, July 19, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced that it has been included in the FTSE4Good Index Series for the second consecutive year. This achievement recognizes WuXi AppTec's exceptional performance in environmental, social, and governance (ESG) practices driven by our commitment to advancing sustainability and enabling innovation for a healthier world.Read moreWuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global CustomersSINGAPORE, May 23, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced the groundbreaking of its new R&D and manufacturing site in Singapore. This milestone, following the announcement of the new site in 2022, marks another step forward in WuXi AppTec’s mission to continuously enhance its CRDMO enabling platform to better support customers worldwide in advancing healthcare treatments and innovations. Read moreWuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations(SHANGHAI, April 29, 2024) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the first quarter ending March 31, 2024 (“Reporting Period”): Read moreWuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time(SHANGHAI, March 18, 2024) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the year ending December 31, 2023 (“Reporting Period”)Read moreCareersWelcome toOur TeamBecome Part of Creating a Better LifeJoin UsInvestorsThe Latest Financial Reports, Announcements and Resources SEE MOREContact UsWuXi AppTec Main Offices288 Fute Zhong RoadWaigaoqiao Free Trade ZoneShanghai 200131, ChinaTel: +86 (21) 5046-1111Fax: +86 (21) 5046-1000EnquiriesTel: 400-820-0985 (Mainland China)857-413-2800 (U.S.)+86 (21) 2066-3734 (Global)Email: wuxiconcierge@wuxiapptec.comSocial MediaSEE OUR GLOBAL SITES© 2020 WuXi AppTecTerms of Use  |  Privacy Policy  |  Transparency in Coverage  |  沪ICP备10016157号  |  沪公网安备31011502012242号© 2020 WuXi AppTecTerms of Use  |  Privacy Policy  |  Transparency in Coverage  |  沪ICP备10016157号沪公网安备31011502012242号enusen-US1730643616https://wuxiapptec.com

اپنی سائٹ میں ترمیم کریں؟

کیا کر رہے ہو؟